Hydrogenology
Hydrogenology editorial study record

Hydrogen inhibits endometrial cancer growth via a ROS/NLRP3/caspase-1/GSDMD-mediated pyroptotic pathway

Yang Y, Liu PY, Bao W, Chen SJ, Wu FS, Zhu PY. · 2020.

PreclinicalOther formsPublished 2020
Study record, not medical adviceThis page reports one source and Hydrogenology’s source-text extraction. It does not establish that molecular hydrogen is effective, safe or appropriate for any person. Human, animal and laboratory evidence must not be treated as equivalent.
Source and classification

What kind of evidence is this?

Evidence stream

Preclinical

Reported design

Controlled endometrial-cancer cell and mouse study

Research topic

Cancer research

Administration classification

Other forms

Study result signal

Positive preclinical signal.

Outcome type

Tumor-growth and mechanistic cell-death outcomes.

Reported in the source

Methods at a glance

Population or model

Human endometrial-cancer cell lines and a mouse tumor model.

Sample

Cell assays and small animal groups; assay-specific counts are reported.

Duration

Article-specific cell exposures and 24-day animal follow-up.

Intervention

Hydrogenated culture medium and hydrogen-water exposure in the animal protocol.

Hydrogen form

H₂ dissolved in culture medium or water.

H₂ specification

Approximately 1.0 ppm in the hydrogenated medium/water under the reported preparation.

H₂ flow

Not applicable.

O₂ delivered with H₂

No oxygen was co-delivered.

Comparator

Conventional medium/water and mechanistic inhibitor comparisons.

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Cell viability, tumor growth, pyroptosis and NLRP3/caspase-1/GSDMD signaling.

Reported result

Hydrogen exposure was reported to reduce tumor growth and alter pyroptosis-related markers in the tested cell and mouse models.

Results-extraction completeness

The full article was checked for methods, intervention details, outcomes, positive and null findings, funding and conflicts. This record does not imply medical efficacy.

A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.

Interpretation limits

Cautions and applicability

Design and reporting cautions

Preclinical evidence only; pathway experiments and multiple laboratory endpoints do not establish clinical efficacy.

Applies directly to

The reported endometrial-cancer cell and mouse models only.

Preliminary appraisal framework

SYRCLE animal-study tool — preliminary

Preliminary risk-of-bias status

Some concerns

Appraisal rationale

Controlled experiments were used, but allocation concealment, blinded assessment and multiplicity handling were unclear.

Appraisal domains

Sequence generation checked where reported · Allocation concealment generally unclear · Personnel blinding generally unclear · Outcome-assessor blinding generally unclear · No prospectively registered analysis plan identified

No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.

Provenance

Sources and record status

Identifiers

PMID: 31924176 · DOI: 10.1186/s12885-019-6491-6

Publisher access

A free full article is available through PubMed Central.

Extraction basis

Official PubMed Central full article and PubMed bibliographic record; source identity, methods, intervention, results, funding and conflicts checked 10 August 2026.

Record revision

2026-08-10